AU2019222705B2 - Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases - Google Patents

Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Info

Publication number
AU2019222705B2
AU2019222705B2 AU2019222705A AU2019222705A AU2019222705B2 AU 2019222705 B2 AU2019222705 B2 AU 2019222705B2 AU 2019222705 A AU2019222705 A AU 2019222705A AU 2019222705 A AU2019222705 A AU 2019222705A AU 2019222705 B2 AU2019222705 B2 AU 2019222705B2
Authority
AU
Australia
Prior art keywords
antibody
flt3l
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019222705A
Other languages
English (en)
Other versions
AU2019222705A1 (en
Inventor
Yan Chen
Rachel ETTINGER
Anna Hansen
Peter Pavlik
Xiaodong Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics Ireland DAC
Original Assignee
Horizon Therapeutics Ireland DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland DAC filed Critical Horizon Therapeutics Ireland DAC
Publication of AU2019222705A1 publication Critical patent/AU2019222705A1/en
Assigned to HORIZON THERAPEUTICS IRELAND DAC reassignment HORIZON THERAPEUTICS IRELAND DAC Request for Assignment Assignors: VIELA BIO, INC.
Application granted granted Critical
Publication of AU2019222705B2 publication Critical patent/AU2019222705B2/en
Priority to AU2026200083A priority Critical patent/AU2026200083A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019222705A 2018-02-14 2019-02-13 Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases Active AU2019222705B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200083A AU2026200083A1 (en) 2018-02-14 2026-01-07 Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630571P 2018-02-14 2018-02-14
US62/630,571 2018-02-14
PCT/US2019/017877 WO2019160976A1 (en) 2018-02-14 2019-02-13 Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200083A Division AU2026200083A1 (en) 2018-02-14 2026-01-07 Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2019222705A1 AU2019222705A1 (en) 2020-10-01
AU2019222705B2 true AU2019222705B2 (en) 2025-10-09

Family

ID=67619040

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019222705A Active AU2019222705B2 (en) 2018-02-14 2019-02-13 Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
AU2026200083A Pending AU2026200083A1 (en) 2018-02-14 2026-01-07 Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200083A Pending AU2026200083A1 (en) 2018-02-14 2026-01-07 Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Country Status (13)

Country Link
US (3) US11512127B2 (https=)
EP (1) EP3752195A4 (https=)
JP (3) JP7525397B2 (https=)
KR (2) KR20250139415A (https=)
CN (2) CN111989117B (https=)
AU (2) AU2019222705B2 (https=)
BR (1) BR112020016400A2 (https=)
CA (1) CA3091184A1 (https=)
CL (1) CL2020002088A1 (https=)
IL (1) IL276598A (https=)
MX (2) MX2020008479A (https=)
SG (1) SG11202007702UA (https=)
WO (1) WO2019160976A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250139415A (ko) 2018-02-14 2025-09-23 호라이즌 테라퓨틱스 아일랜드 디에이씨 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067760A2 (en) * 2001-01-09 2002-09-06 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3306063B2 (ja) 1990-08-24 2002-07-24 イグジス， インコーポレイテッド ランダムコドンを有するオリゴヌクレオチドを合成する方法
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7537932B1 (en) 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
US7045128B2 (en) * 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US6630143B1 (en) * 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6602994B1 (en) 1999-02-10 2003-08-05 Hercules Incorporated Derivatized microfibrillar polysaccharide
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2005500508A (ja) * 2000-06-28 2005-01-06 アメリカ合衆国 ガスセンサのための気体ガス採取装置及びその方法
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
US20060142430A1 (en) 2004-12-29 2006-06-29 Harrington John C Retention and drainage in the manufacture of paper
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
EP2491177B1 (de) 2009-10-20 2020-02-19 Solenis Technologies Cayman, L.P. Verfahren zur herstellung von papier, pappe und karton mit hoher trockenfestigkeit
US20130156764A1 (en) * 2010-03-12 2013-06-20 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
CN107073070A (zh) * 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
KR20250139415A (ko) 2018-02-14 2025-09-23 호라이즌 테라퓨틱스 아일랜드 디에이씨 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067760A2 (en) * 2001-01-09 2002-09-06 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays

Also Published As

Publication number Publication date
US20230056815A1 (en) 2023-02-23
MX2020008479A (es) 2020-11-24
EP3752195A4 (en) 2021-11-17
KR102903323B9 (ko) 2026-02-13
US11512127B2 (en) 2022-11-29
AU2026200083A1 (en) 2026-02-05
US20250122276A1 (en) 2025-04-17
KR20200135331A (ko) 2020-12-02
AU2019222705A1 (en) 2020-10-01
WO2019160976A1 (en) 2019-08-22
SG11202007702UA (en) 2020-09-29
US20210002360A1 (en) 2021-01-07
EP3752195A1 (en) 2020-12-23
IL276598A (en) 2020-09-30
BR112020016400A2 (pt) 2020-12-15
JP7756686B2 (ja) 2025-10-20
CN119971026A (zh) 2025-05-13
CA3091184A1 (en) 2019-08-22
JP2025013590A (ja) 2025-01-24
JP7525397B2 (ja) 2024-07-30
JP2023139148A (ja) 2023-10-03
US12209123B2 (en) 2025-01-28
JP2021513357A (ja) 2021-05-27
RU2020129978A (ru) 2022-03-14
CL2020002088A1 (es) 2020-12-11
CN111989117B (zh) 2025-02-18
KR20250139415A (ko) 2025-09-23
KR102903323B1 (ko) 2025-12-23
MX2024015370A (es) 2025-02-10
CN111989117A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
CN111194323B (zh) 多特异性抗体
EP4347655A1 (en) Anti-ccr8 antibodies and uses thereof
CN112566935A (zh) 抗ox40抗体和使用方法
TWI790548B (zh) 抗人類cd19抗體
KR20200063153A (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
US20240309087A1 (en) Anti-cd112r antibody and use thereof
JP2023531493A (ja) Ｉｌ－１０突然変異タンパク質及びその融合タンパク質
AU2026200083A1 (en) Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
IL281767B1 (en) Antibodies directed against CD137 and methods of using them
CN112512572B (zh) 抗cd40抗体及其用途
CN114641500A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
HK40041682A (en) Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
RU2788128C2 (ru) Антитела к лиганду рецепторной тирозинкиназы 3, подобной продукту протоонкогена вируса саркомы кошек (fms) штамма mcdonough (flt3l), и варианты их применения для лечения аутоиммунных и воспалительных заболеваний
KR20240139083A (ko) Btla에 대한 항체 및 이의 용도
CN117858899A (zh) 抗ccr8抗体及其用途
TW202222831A (zh) 抗-OX40L抗體、抗OX40L和抗-TNFα雙特異性抗體及其用途
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40050839A (en) Anti-ox40 antibodies and methods of use
TW201925234A (zh) 抗huTNFR1治療非酒精性脂肪性肝炎
EA049160B1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HORIZON THERAPEUTICS IRELAND DAC

Free format text: FORMER APPLICANT(S): VIELA BIO, INC.

FGA Letters patent sealed or granted (standard patent)